Pharmacokinetics and Metabolism of Macrolides

Macrolide Antibiotics: Chemistry, Biology, and Practice: Second Edition

Volumn , Issue , 2003, Pages 327-361

  Kohno, Yoshiro ^a  

^a TAISHO PHARMACEUTICAL CO LTD   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 17044374574     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-012526451-8/50007-2     Document Type: Chapter

References (135)

1. Bryskier A. Newer macrolides and their potential target organisms. Curr. Opin. Infect. Dis. 1992, 5:764-772.
2. Mazzei T., Mini E., Novelli A., Periti P. Chemistry and mode of action of macrolides. J. Antimicrob. Chemother. 1993, 31(Suppl. C):1-9.
3. Periti P., Mazzei T. Clarithromycin: Pharmacokinetic and pharmacodynamic interrelationships and dosage regimen. J. Chemother. 1999, 11:11-27.
4. Periti P., Mazzei T., Mini E., Novelli A. Pharmacokinetic interactions of macrolides. Clin. Pharmacokinet. 1992, 23:106-131.
5. Von Rosenstiel N.A., Adam D. Macrolide antibacterials: Drug interactions of clinical significance. Drug Safety 1995, 13:105-122.
6. Amsden G.W. Macrolides versus azalides: A drug interaction update. Ann. Pharmacother. 1995, 29:906-917.
7. Williams J.D., Sefton A.M. Comparison of macrolide antibiotics. J. Antimicrob. Chemother. 1993, 31(Suppl. C):11-26.
8. Lazarevski T., Radobolja G., Djokic S. Erythromycin VI: Kinetics of acidcatalyzed hydrolysis of erythromycin oxime and erythromycylamine. J. Pharm. Sci. 1978, 67:1031-1033.
9. Wilson J.T., vanBoxtel C.J. Pharmacokinetics of erythromycin in man. Antibiot. Chemother. 1978, 25:181-203.
10. Omura S., Tsuzuki K., Sunazuka T. Macrolides with gastrointestinal motor stimulating activity. J. Med. Chem. 1987, 30:1941-1943.
11. Kirst H.A., Sides G.D. New directions for macrolide antibiotics: Structural modifications and in vitro activity. Antimicrob. Agents Chemother. 1989, 33:1413-1418.
12. Ginsburg C.M. Pharmacology of erythromycin in infants and children. Pediatr. Infect. Dis. J. 1986, 5:124-129.
13. Reed M.D., Blumer J.L. Azithromycin: A critical review of the first azilide antibiotic and its role in pediatric practice. Pediatr. Infect. Dis. J. 1997, 16:1069-1083.
14. Stein G.E., Havlichek D.H. The new macrolide antibiotics. Azithromycin and clarithromycin. Postgrad. Med. 1992, 92:269-281.
15. Griffith R.S., Black H.R. Comparison of the blood levels obtained after single and multiple doses of erythromycin estolate and erythromycin stearate. Am. J. Med. Sci. 1964, 247:69-74.
16. Osono T., Umezawa H. Pharmacokinetics of macrolides, lincosamides and streptogramins. J. Antimicrob. Chemother. 1985, 16(Suppl. A):151-166.
17. Chun A.H., Seitz J.A. Pharmacokinetics and biological availability of erythromycin. Infection 1977, 5(Suppl. 1):14-22.
18. Philipson A., Sabath L.D., Charles D. Transplacental passage of erythromycin and clindamycin. N. Engl. J. Med. 1973, 288:1219-1221.
19. Alvarez-Elcoro S., Enzler M.J. The macrolides: Erythromycin, clarithromycin, and azithromycin. Mayo Clin. Proc. 1999, 74:613-634.
20. Disse B., Gundert-Remy U., Weber E., Andrassy K., Sietzen W., Lang A. Pharmacokinetics of erythromycin in patients with different degrees of renal impairment. Int. J. Clin. Pharmacol. Ther. Toxicol. 1986, 24:460-464.
21. Hall K.W., Nightingale C.M., Gibaldi M., Nelson E., Bates T.R., Di Santo A.R. Pharmacokinetics of erythromycin in normal and alcoholic liver disease subjects. J. Clin. Pharmacol. 1982, 25:321-325.
22. Markham A., Faulds D. Roxithromycin: An update of its antimicrobial activity, pharmacokinetic properties and therapeutic use. Drugs 1994, 48:297-326.
23. Nilsen O.G. Comparative pharmacokinetics of macrolides. J. Antimicrob. Chemother. 1987, 20(Suppl. B):81-88.
24. Birkett D.J., Robson R.A., Grgurinovich N., Tonkin A. Single oral dose pharmacokinetics of erythromycin and roxithromycin and the effects of chronic dosing. Ther. Drug. Monit. 1990, 12:65-71.
25. Puri S.K., Lassman H.B. Roxithromycin: A pharmacokinetic review of a macrolide. J. Antimicrob. Chemother. 1987, 20(Suppl. B):89-100.
26. Zini R., Fournet M.P., Barre J., Tremblay D., Tillement J.P. In vitro study of roxithromycin binding to serum proteins and erythrocytes in humans. Br. J. Clin. Pract. 1988, 42(Suppl. 55):54.
27. Bahal N., Nahata M.C. The new macrolide antibiotics: Azithromycin, clarithromycin, dirithromycin, and roxithromycin. Ann. Pharmacother. 1992, 26:46-55.
28. Falchi M., Teodori F., Carraro A., Cioce C., Scaglione F., Braga P.C. Penetration of erythromycin into tonsillar tissue. Curr. Med. Res. Opin. 1985, 9:611-615.
29. Tremblay D., Mignot A., Courand L., Manuel C. Concentrations of roxithromycin (RU28965), a new macrolide, in lung tissue after repeated dosing. Abstr. No. 1205 1986.
30. Bergogne-Bérézin E. Tissue distribution of roxithromycin. J. Antimicrob. Chemother. 1987, 20(Suppl. B):113-120.
31. Brun Y., Forey F., Gammondes J.P. Levels of erythromycin in pulmonary tissue and bronchial mucus compared to those of amoxycillin. J. Antimicrob. Chemother. 1981, 8:459-466.
32. Cars O. Pharmacokinetics of antibiotics in tissue and tissue fluids: A review. Scand. J. Infect. Dis. 1991, 74(Suppl.):23-33.
33. Tremblay D., Jaeger H., Fourtillan J.B., Manual C. Pharmacokinetics of three single doses (150, 300, 450 mg) of roxithromycin in young volunteers. Br. J. Clin. Pract. 1988, 42(Suppl. 55):51.
34. Koyama M., Tateno M., Shirotsuka M., Yamamoto M., Hirayama M., Saitoh K., Okui K. Absorption, metabolism and excretion of RU 28965 in humans. Chemotherapy 1988, 36:164-183.
35. Yamazaki H., Shimada T. Comparative studies of in vitro inhibition of cytochrome P-450 3A4-dependent testosterone 6β-hydroxylation by roxithromycin and its metabolites, troleandomycin, and erythromycin. Drug Metab. Dispos. 1998, 26:1053-1057.
36. Delaforge M., Sartori E., Mansuy D. In vivo and in vitro effects of a new macrolide antibiotic roxithromycin on rat liver cytochrome P-450: Comparison with troleandomycin and erythromycin. Chem. Biol. Interact. 1988, 68:179-188.
37. Yamazaki H., Urano T., Hiroki S., Shimada T. Effects of erythromycin and roxithromycin on oxidation of testosterone and nifedipine catalyzed by CYP3A4 in human liver microsomes. J. Toxicol. Sci. 1996, 21:215-226.
38. Yamazaki H., Hiroki S., Urano T., Inoue K., Shimada T. Effects of roxithromycin, erythromycin and troleandomycin on their N-demethylation by rat and human cytochrome P-450 enzymes. Xenobiotica 1996, 26:1143-1153.
39. Petri P., Mazzei T. Pharmacokinetics of roxithromycin in renal and hepatic failure and drug interactions. J. Antimicrob. Chemother. 1987, 20(Suppl. B):107-112.
40. Tremblay D., Verger C., Saint-Salvi B., Robinet D., Manuel C. Pharmacokinetics of roxithromycin in chronic renal insufficiency. Br. J. Clin. Pract. 1988, 42(Suppl. 55):61-62.
41. Lebrec D., Benhamou J.P., Fourtillan J.B., Tremblay D., Saint-Salvi B., Manuel C. Roxithromycin: Pharmacokinetics in patients suffering from alcoholic cirrhosis. Br. J. Clin. Pract. 1988, 42(Suppl. 55):63.
42. Morimoto S., Takahashi Y., Watanabe Y., Omura S. Chemical modification of erythromycin. I. Synthesis and antibacterial activity of 6-O-methylerythromycins A. J. Antibiot. 1984, 37:187-189.
43. Zuckerman J.M. The newer macrolides: Azithromycin and clarithromycin. Infect. Dis. Clin. North Am. 2000, 14:449-462.
44. Chu S.Y., Deaton R., Cavanaugh J. Absolute bioavailability of clarithromycin after oral administration in humans. Antimicrob. Agents Chemother. 1992, 36:1147-1150.
45. Hardy D.J., Guay D.R.P., Jones R.N. Clarithromycin, a unique macrolide: A pharmacokinetic, microbiological, and clinical overview. Diagn. Microbiol. Infect. Dis. 1992, 15:39-53.
46. Nightingale C.H. Pharmacokinetics and pharmacodynamics of newer macrolides. Pediatr. Infect. Dis. J. 1997, 16:438-443.
47. Wise R. The development of macrolides and related compounds-Leading article. J. Antimicrob. Chemother. 1989, 23:299-300.
48. Piscitelli S.C., Danziger L.H., Rodvold K.A. Clarithromycin and azithromycin: New macrolide antibiotics. Clin. Pharm. 1992, 11:137-152.
49. LeBel M. Comparative pharmacokinetics of new macrolides. Can. J. Infect. Dis. 1993, 4:149-151.
50. Ferrero J.L., Bopp B.A., Marsh K.C., Quigley S.C., Johnson M.J., Anderson D.J., Lamm J.E., Tolman K.G., Sanders S.W., Cavanaugh J.H., Sonders R.C. Metabolism and disposition of clarithromycin in man. Drug Metab. Dispos. 1990, 18:441-446.
51. Chu S.Y., Sennello L.T., Bunnell S.T., Varga L.L., Wilson D.S., Sonders R.C. Pharmacokinetics of clarithromycin, a new macrolide, after single ascending oral doses. Antimicrob. Agents Chemother. 1992, 36:2447-2453.
52. Chu S.Y., Wilson D.S., Deaton R.L., Mackenthum A.V., Eason C.N., Cavanaugh J.H. Single- and multiple-dose pharmacokinetics of clarithromycin, a new macrolide antimicrobial. J. Clin. Pharmacol. 1993, 33:719-726.
53. Saito A., Ishikawa Y., Shinohara M., Fukuhara I., Nakayama I., Tomizawa M., Sato K. Preclinical and clinical studies on TE-031 (A-56268). Chemotherapy (Tokyo) 1988, 36(Suppl. 3):521-537.
54. Sedlmayr T., Peters F., Raasch W., Kees F. Clarithromycin, a new macrolide antibiotic. Effectiveness in puerperal infections and pharmacokinetics in breast milk [in German]. Geburtshilfe Frauenheilkd. 1993, 53:488-491.
55. Carbon C. Clinical relevance of intracellular and extracellular concentrations of macrolides. Infection 1995, 23:10-14.
56. Peters D.H., Clissold S.P. Clarithromycin; A review of its antimicrobial activity, pharmacokinetic properties and therapeutic potential. Drugs 1992, 44:117-164.
57. Fish D.N., Gotfried M.H., Danziger L.H., Rodvold K.A. Penetration of clarithromycin into lung tissues from patients undergoing lung resection. Antimicrob. Agents Chemother. 1994, 38:876-878.
58. Langtry H.D., Brogden R.N. Clarithromycin. A review of its efficacy in the treatment of respiratory tract infections in immunocompetent patients. Drugs 1997, 53:973-1004.
59. Rodvold K.A., Gotfried M.H., Danziger L.H., Servi R.J. Intrapulmonary steady-state concentrations of clarithromycin and azithromycin in healthy adult volunteers. Antimicrob. Agents Chemother. 1997, 41:1399-1402.
60. Kohno Y., Yoshida H., Suwa T., Suga T. Comparative pharmacokinetics of clarithromycin (TE-031), a new macrolide antibiotic, and erythromycin in rats. Antimicrob. Agents Chemother. 1989, 33:751-756.
61. Kohno Y., Yoshida H., Suwa T., Suga T. Uptake of clarithromycin by rat lung cells. J. Antimicrob. Chemother. 1990, 26:503-513.
62. Fietta A., Merlini C., Gialdroni-Grassi G. Requirements for intracellular accumulation and release of clarithromycin and azithromycin by human phagocytes. J. Chemother. 1997, 9:23-31.
63. Ishiguro M., Koga H., Kohno S., Hayashi T., Yamaguchi K., Hirota M. Penetration of macrolides into human polymorphonuclear leukocytes. J. Antimicrob. Chemother. 1989, 24:719-729.
64. Raghoebar M., Lindeyer E., Van den Berg W.B., Van Ginneken C.A.M. On the mechanisms of association of the macrolide antibiotic erythromycin with isolated human polymorphonuclear leucocytes. Biochem. Pharmacol. 1988, 38:3221-3227.
65. Laufen H., Wildfeuer A., Lach P. Mechanism of azithromycin uptake in human polymorphonuclear leucocytes. Arzneim-Forsch./Drug Res. 1990, 40:686-689.
66. Mtairag E.M., Abdelghaffar H., Labro M.T. Investigation of dirithromycin and erythromycylamine uptake by human neutrophils in vitro. J. Antimicrob. Chemother. 1994, 33:523-536.
67. Hand W.L., Hand D.L. Interactions of dirithromycin with human polymorphonuclear leukocytes. Antimicrob. Agents Chemother. 1993, 37:2557-2562.
68. Prokesch R.C., Hand W.L. Antibiotic entry into human polymorphonuclear leukocytes. Antimicrob. Agents Chemother. 1982, 21:373-380.
69. Hand W.L., King-Thompson N., Holman J.W. Entry of roxithromycin (RU965), imipenem, cefotaxime, trimethoprim and metronidazole into human polymorphonuclear leukocytes. Antimicrob. Agents Chemother. 1987, 31:1553-1557.
70. Laufen H., Wildfeuer A. Kinetics of the uptake of antimicrobial agents by human polymorphonuclear leucocytes. Arzneim-Forsch./Drug Res. 1989, 39:233-235.
71. Rodrigues A.D., Roberts E.M., Mulford D.J., Yao Y., Quellet D. Oxidative metabolism of clarithromycin in the presence of human liver microsomes. Major role for the cytochrome P-450 3A (CYP3A) subfamily. Drug Metab. Dispos. 1997, 25:623-630.
72. Sturgill M.G., Rapp R.P. Clarithromycin: Review of a new macrolide antibiotic with improved microbiological spectrum and favorable pharmacokinetic and adverse effect profiles. Ann. Pharmacother. 1992, 26:1099-1108.
73. Davey P.G. The pharmacokinetics of clarithromycin and its 14-OH metabolite. J. Hosp. Infect. 1991, 19(Suppl. A):29-37.
74. Chu S.Y., Granneman G.R., Pichotta P.J., Decourt J.P., Girault J., Fourtillar J.B. Effect of moderate or severe hepatic impairment on clarithromycin pharmacokinetics. J. Clin. Pharmacol. 1993, 33:480-485.
75. Zuckerman J.M., Kaye K.M. The new macrolides. Azithromycin and clarithromycin. Inf. Dis. Clin. North Am. 1995, 9:731-745.
76. Foulds G., Shepard R.M., Johnson R.B. The pharmacokinetics of azithromycin in human serum and tissues. J. Antimicrob. Chemother. 1990, 25(Suppl. A):73-82.
77. Foulds G., Luke D.R., Teng R., Willavize S.A., Freidman H., Curatolo W.J. The absence of an effect of food on the bioavailability of azithromycin administered as tablets, sachet or suspension. J. Antimicrob. Chemother. 1996, 37(Suppl. C):37-44.
78. Schentag J.J., Ballow C.H. Tissue-directed pharmacokinetics. Am. J. Med. 1991, 91(Suppl. 3A):5S-11S.
79. Nahata M.C., Koranyi K.I., Luke D.R., Foulds G. Pharmacokinetics of azithromycin in pediatric patients with acute otitis media. Antimicrob. Agents Chemother. 1995, 39:1875-1877.
80. Mazzei T., Surrenti C., Novelli A., Crispo A., Fallani S., Carla V., Surrenti E., Periti P. Pharmacokinetics of azithromycin in patients with impaired depatic function. J. Antimicrob. Chemother. 1993, 31(Suppl. E):57-63.
81. Dette G.A., Knothe H. The binding of erythromycin in human serum. Biochem. Pharmacol. 1986, 35:959-966.
82. Bothe R., Mattie H., van den Broek P.J. Levels of azithromycin and alpha-1 acid glycoprotein in serum in patients with community-acquired pneumonia. Antimicrob. Agents Chemother. 1995, 39:2801-2802.
83. Girard A.E., Girard D., English A.R., Gootz T.D., Cimochowski C.R., Faiella J.A., Haskell S.L., Retsema J.A. Pharmacokinetics and in vivo studies with azithromycin (CP-62,993), a new macrolide with an extended half-life and excellent tissue distribution. Antimicrob. Agents Chemother. 1987, 31:1948-1954.
84. Davila D., Kolacny-Babic L., Plavsic F. Pharmacokinetics of azithromycin after single oral dosing of experimental animals. Biopharm. Drug Dispos. 1991, 12:505-514.
85. Baldwin D.R., Wise R., Andrews J.M., Ashby J.P., Honeybourne D. Azithromycin concentrations at the sites of pulmonary infection. Eur. Respir. J. 1990, 3:886-890.
86. Morris D.L., De Souza A., Jones J.A., Morgan W.E. High and prolonged pulmonary tissue concentrations of azithromycin following a single oral dose. Eur. J. Clin. Microbiol. Infect. Dis. 1991, 10:859-861.
87. Jaruratanasirikul S., Hortiwakul R., Tantisarasart T., Phuenpathom N., Tussanasunthornwong S. Distribution of azithromycin into brain tissue, cerebrospinal fluid, and aqueous humor of the eye. Antimicrob. Agents Chemother. 1996, 40:825-826.
88. Kelsey J.J., Moser L.R., Jennings J.C., Munger M.A. Presence of azithromycin breast milk concentrations: A case report. Am. J. Obstet. Gynecol. 1994, 170:1375-1376.
89. Gladue R.P., Bright G.M., Isaacson R.E., Newborg M.F. In vitro and in vivo uptake of azithromycin (CP-62,993) by phagocytic cells: Possible mechanism of delivery and release at sites of infection. Antimicrob. Agents Chemother. 1989, 33:277-282.
90. Bonnet M., Van der Auwera P. In vitro and in vivo intraleukocytic accumulation of azithromycin (CP-62,993) and its influence on ex vivo leukocyte chemiluminescence. Antimicrob. Agents Chemother. 1992, 36:1302-1309.
91. Shepard R.M., Falkner F.C. Pharmacokinetics of azithromycin in rats and dogs. J. Antimicrob. Chemother. 1990, 25(Suppl. A):49-60.
92. Doern G.V., Brueggemann A., Holley H.P., Rauch A.M. Antimicrobial resistance of Streptococcus pneumoniae recovered from outpatients in the United States during the winter months of 1994 to 1995: Results of a 30-center national surveillance study. Antimicrob. Agents Chemother. 1996, 40:1208-1213.
93. Doern G.V., Brueggemann A., Pierce G., Hogan T., Holley H.P., Rauch A. Prevalence of antimicrobial resistance among 723 outpatient clinical isolates of Moraxella catarrhalis in the United States in 1994 and 1995: Results of a 30-center national surveillance study. Antimicrob. Agents Chemother. 1996, 40:2884-2886.
94. Doern G.V., Brueggemann A., Pierce G., Holley H.P., Rauch A. Antibiotic resistance among clinical isolates of Haemophilus influenzae in the United States in 1994 to 1995 and detection of lactamase positive strains resistant to amoxicillin-clavulanate: Results of national multicenter surveillance study. Antimicrob. Agents Chemother. 1997, 41:292-297.
95. Biedenbach D.J., Barrett M.S., Jones R.N. Comparative antimicrobial activity and kill-curve investigations of novel ketolide antimicrobial agents (HMR 3004 and HMR 3647) tested against Haemophilus influenzae and Moraxella catarrhalis strains. Diagn. Microbiol. Infect. Dis. 1998, 31:349-353.
96. Roblin P.M., Hammerschlag M.R. In vitro activity of a new ketolide antibiotic, HMR 3647, against Chlamydia pneumoniae. Antimicrob. Agents Chemother. 1998, 42:1515-1516.
97. Pankuch G.A., Visalli M.A., Jacobs M.R., Appelbaum P.C. Susceptibilities of penicillin- and erythromycin-susceptible and -resistant pneumococci to HMR 3647 (RU 66647), a new ketolide, compared with susceptibilities to 17 other agents. Antimicrob. Agents Chemother. 1998, 42:624-630.
98. Namour F., Wessels D.H., Pascual M.H., Reynolds D., Sultan E., Lenfant B. Pharmacokinetics of the new ketolide telithromycin (HMR 3647) administered in ascending single and multiple doses. Antimicrob. Agents Chemother. 2001, 45:170-175.
99. Lenfant B., Sultan E., Wable C., Pascual M.H., Meyer B.H. Pharmacokinetics of 800-mg once-daily oral dosing of the ketolide HMR 3647 in healthy young volunteers. "Program of the 38th Interscience Conference of Antimicrobial Agents and Chemotherapy", Abstr. No. A-49 1998, 16. American Society of Microbiology, Washington, DC.
100. Lenfant B., Perret C., Pascual M.H. The bioavailability of HMR 3647, a new once-daily ketolide antimicrobial, is unaffected by food. Proceedings of the 21st International Congress on Chemotherapy 1999, Vol. 44:69. Oxford University Press, Oxford, UK.
101. Sultan E., Namour F., Mauriac C., Lenfant B., Scholtz H. HMR 3647, a ketolide antimicrobial, is metabolised and excreted mainly in faeces in man. Proceedings of the 21st International Congress on Chemotherapy 1999, Vol. 44:63. Oxford University Press, Oxford, UK.
102. Sultan E., Lenfant B., Wable C., Pascual M.H., Meyer B. Pharmacokinetic profile of HMR 3647 800 mg once-daily in elderly volunteers. Proceedings of the 21st International Congress on Chemotherapy 1999, Vol. 44:66. Oxford University Press, Oxford, UK.
103. Vazifeh D., Preira A., Bryskier A., Labro M.T. Interactions between HMR 3647, a new ketolide, and human polymorphonuclear neutrophils. Antimicrob. Agents Chemother 1998, 42:1944-1951.
104. Gia H.P., Roeder V., Namour F., Sultan E., Lenfant B. HMR 3647 achieves high and sustained concentrations in white blood cells in man. Proceedings of the 21st International Congress on Chemotherapy 1999, Vol. 44:79. Oxford University Press, Oxford, UK.
105. Serieys C.M., Cantalloube C., Soler P., Lemaitre F., Gia H.P., Brunner F., Andremont A. HMR 3647 achieves high and sustained concentrations in broncho-pulmonary tissues. Proceedings of the 21st International Congress on Chemotherapy 1999, Vol. 44:78. Oxford University Press, Oxford, UK.
106. Neuhauser M.M., Prause J.L., Li D.H., Jung R., Boyea N., Hackleman J.M., Danziger L.H., Pendland S.L. In vitro bactericidal activity of ABT-773, a new ketolide, versus clarithromycin, azithromycin, ciprofloxacin, amoxicillin/clavulanate against penicillin/erythromycin sensitive and resistant Streptococcus pneumoniae and Haemophilus influenzae. "Program of the 39th Interscience Conference of Antimicrobial Agents and Chemotherapy", Abstr. No. 2139 1999, 347. American Society of Microbiology, Washington, DC.
107. Hernandez L., Sadrzadeh N., Krill S., Ma Z., Marsh K. Preclinical pharmacokinetic profile of ABT-773 in mouse, rat, monkey, and dog. "Program of the 39th Interscience Conference of Antimicrobial Agents and Chemotherapy", Abstr. No 2148 1999, 350. American Society of Microbiology, Washington, DC.
108. 14C]ABT-773. "Program of the 39th Interscience Conference of Antimicrobial Agents and Chemotherapy", Abstr. No. 2149 1999, 350. American Society of Microbiology, Washington, DC.
109. Reisz G., Pingletone S.K., Melethil S., Ryan P.B. The effect of erythromycin on theophylline pharmacokinetics in chronic bronchitis. Am. Rev. Respir. Dis. 1983, 127:581-584.
110. Backmann K., Schwartz J.I., Forney R., Frogameni A., Jauregui L.E. The effect of erythromycin on the disposition kinetics of warfarin. Pharmacology 1984, 28:171-176.
111. Wong Y.Y., Ludden T.M., Bell R.D. Effect of erythromycin on carbamazepine kinetics. Clin. Pharmacol. Ther. 1983, 33:460-464.
112. Martell R., Heinrichs D., Stiller C.R., Jenner M., Keown P.A., Dupre J. The effects of erythromycin in patients treated with cyclosporine. Ann. Intern. Med. 1986, 104:660-661.
113. Horn J.R., Hansten P.D. Drug interactions with antibacterial agents. J. Fam. Pract. 1995, 41:81-90.
114. Guay D.R.P. Formulary management of macrolide antibotics. Pharmacoeconomics 1995, 8:491-512.
115. Babany G., Larrey D., Pessayre D. Macrolide antibiotics as inducers and inhibitors of cytochrome P-450 in experimental animals and man. Progress in Drug Metabolism 1988, 61-98. Taylor and Francis, London. G.G. Gibson (Ed.).
116. Delaforge M., Jaouen M., Mansuy D. Dual effects of macrolide antibiotics on rat liver cytochrome P-450. Induction and formation of metabolite complexes: A structure-activity relationship. Biochem. Pharmacol. 1983, 32:2309-2318.
117. Tinel M., DeScatoire V., Larrey D., Loeper J., Labbe G., Letteron P., Pessayre D. Effect of clarithromycin on cytochrome P-450. Comparison with other macrolides. J. Pharmacol. Exp. Ther. 1989, 250:746-751.
118. Rodin S.M., Johnson B.F. Pharmacokinetic drug interactions with digoxin. Clin. Pharmacokinet. 1988, 15:227-244.
119. Surjus A., Tremblay D., Saint-Salvi B., Granier J., Lefebvre M.A. Pharmacokinetic interaction of a new macrolide, roxithromycin (RU 28965) with theophyllin. Abstr. No. 1203 1986.
120. Farrington E. Macrolide antibiotics. Pediatr. Nurs. 1998, 23:433-446.
121. Ruff F., Chu S.Y., Sonders R.C., Sennello L.T. Effects of multiple doses of clarithromycin on the pharmacokinetics of theophylline. "Program of the 30th Interscience Conference on Antimicrobial Agents and Chemotherapy", Abstr. No. 761 1990, 213. American Society of Microbiology, Washington, DC.
122. Gorski J.C., Jones D.R., Haehner-Daniels B.D., Hamman M.A., O'Mara E.M., Hall S.D. Pharmacokinetics and drug disposition. The contribution of intestinal and hepatic CYP3A to the interaction between midazolam and clarithromycin. Clin. Pharmacol. Ther. 1998, 64:133-143.
123. Vance E., Watson-Bitar M., Gustavson L., Kazanjian P. Pharmacokinetics of clarithromycin and zidovudine in patients with AIDS. Antimicrob. Agents Chemother. 1995, 39:1355-1360.
124. Polis M.A., Piscitelli S.C., Vogel S., Witebsky F.G., Conville P.S., Petty B., Kovacs J.A., Davey R.T., Walker R.E., Falloon J., Metcalf J.A., Craft C., Lane H.C., Masur H. Clarithromycin lowers plasma zidovudine levels in person with human immunodeficiency virus infection. Antimicrob. Agents Chemother. 1997, 41:1709-1714.
125. Gillum J.G., Bruzzese V.L., Israel D.S., Kaplowitz L.G., Polk R.E. Effect of clarithromycin on the pharmacokinetics of 2',3'-dideoxyinosine in patients who are seropositive for human immunodeficiency virus. Clin. Infect. Dis. 1996, 22:716-718.
126. Fraschini F., Scaglione F., Demartini G. Clarithromycin clinical pharmacokinetics. Clin. Pharmacokinet. 1993, 25:189-204.
127. Quellet D., Hsu A., Granneman G.R., Carlson G., Guenther H., Mukherjee D., Locke C., Leonard J.M. Assessment of the pharmacokinetic interaction between ritonavir and clarithromycin. Clin. Pharmacol. Ther. 1996, 59:143.
128. Wallace R.J., Brown B.A., Griffith D.E., Girard W., Tanaka K. Reduced serum levels of clarithromycin in patients treated with multidrug regimens including rifampin or rifabutin for Mycobacterium avium-M. intracellulare infection. J. Infect. Dis. 1995, 171:747-750.
129. Sketris I.S., Wright M.R., West M.L. Possible role of the intestinal P-450 enzyme system in a cyclosporine-clarithromycin interaction. Pharmacotherapy 1996, 16:301-305.
130. Honig P.K., Wortham D.C., Zamani K., Cantilena L.R. Comparison of the effect of the macrolide antibiotics erythromycin, clarithromycin and azithromycin, on terfenadine steady-state pharmacokinetics and electrocardiographic parameters. Drug Invest. 1994, 7:148-156.
131. Rapeport W.G., Dewland P.M., Muirhead D.C., Forster P.L. Lack of an interaction between azithromycin and carbamazepine. Br. J. Clin. Pharmacol. 1992, 33. 551P.
132. Harris S., Hilligoss D.M., Colangelo P.M., Eller M., Okerholm R. Azithromycin and terfenadine: Lack of drug interaction. Clin. Pharmacol. Ther. 1994, 58:310-315.
133. Chave J.P., Munafo A., Chatton J.Y., Dayer P., Glauser M.P., Biollaz J. Once-a-week azithromycin in AIDS patients: Tolerability, kinetics, and effects on zidovudine disposition. Antimicrob. Agents Chemother. 1992, 36:1013-1018.
134. Nahata M. Drug interactions with azithromycin and the macrolides: An overview. J. Antimicrob. Chemother. 1996, 37:133-142.
135. Labbe G., Flor M., Lenfant B. HMR 3647, a new ketolide antimicrobial, does not inhibit cytochrome P-450 activity in vitro. Proceedings of the 21st International Congress on Chemotherapy 1999, Vol. 44:95. Oxford University Press, Oxford, UK.